UCSF Neurological Surgery faculty since 2008
Read about Dr. Aghi's current research
Dr. Aghi specializes in adult brain tumors. He is experienced in the surgical treatment of glioneuronal neoplasms, pituitary tumors, and intraoperative mapping of brain function to optimize tumor resection. Dr. Aghi has extensive basic science research interests, including glioma angiogenesis and the use of oncolytic herpes simplex-derived viruses to treat glioblastoma.
Education, Training, and Previous Positions
1993: BS, MS, Stanford University
2000: MD, PhD, Harvard Medical School
2000-2007: Residency, Neurological Surgery, Massachusetts General Hospital
2007: Instructor, Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School
Selected Professional Memberships and Appointments
Society for Neuro-Oncology
American Association of Neurological Surgeons (AANS)
Congress of Neurological Surgeons (CNS)
AANS and CNS, Joint Section for Tumors
Selected Honors and Awards
2004: Preuss Resident Research Award, American Association of Neurologic Surgeons and Congress of Neurological Surgeons
2005: Ronald L. Bittner Award, American Association of Neurologic Surgeons (AANS)
2005: William Scoville Resident Research Award, New England Neurosurgery meeting
2005: Congress of Neurologic Surgeons (CNS) Resident Research Award
2005: American Academy of Neurologic Surgeons Resident Research Award
2006: Mahaley Award, American Association of Neurologic Surgeons
2006: Integra Foundation Award, Congress of Neurologic Surgeons
2007: Synthes Skull Base Award, Congress of Neurologic Surgeons
Research Support
Grant: American Brain Tumor Association (ABTA) Basic Research Fellowship
Title: Role of oncogene expression in the ability of arrested glioma cells to support HSV vector replication
Principal Investigator: Aghi MK
Total Project Period: 6/01/04-6/01/06
Role: Principal Investigator
Specific aims: To define whether p16 and p53 mutations enable arrested glioblastoma cells to support replication of ribonucleotide reductase-mutated oncolytic herpes simplex viruses.
Grant: National Brain Tumor Foundation (NBTF) Charles B. Wilson Award
Title: Stem Cells for Brain Tumors
Principal Investigator: Chiocca EA
Total Project Period: 6/01/01-6/01/02
Role: Co-Investigator
Specific aims: To identify molecular mediators of vasculogenesis, in particular how glioblastomas recruit endothelial progenitor cells to form new blood vessels.
Contact
Manish K. Aghi, MD, PhD
University of California, San Francisco
Department of Neurological Surgery
505 Parnassus Avenue, Room M779
San Francisco, CA 94143-0112
Phone: 415-353-1172 (academic), 415-353-7500 (clinical)
Fax: 415-353-3907 (academic), 415-353-2889 (clinical)
E-mail: AghiM@neurosurg.ucsf.edu
Selected Recent Publications
Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007;67(2):440-4.
Aghi MK, Eskandar EN, Carter BS, Curry WT Jr, Barker FG 2nd. Increased prevalence of obesity and obesity-related postoperative complications in male patients with meningiomas. Neurosurgery 2007;61(4):754-60; discussion 760-1.
Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.J Natl Cancer Inst 2006;98(1):38-50.
Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006;66(18):9054-64.
Aghi M, Kluwe L, Webster MT, Jacoby LB, Barker FG 2nd, Ojemann RG, Mautner VF, MacCollin M. J Neurosurg 2006;104(2):201-7.
Aghi M, Chiocca EA. Gene therapy for glioblastoma. Neurosurg Focus 2006;20(4):E18.
Aghi M, Barker FG 2nd. Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg 2006;19:80-96.
Aghi M, Kiehl TR, Brisman JL. Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature [Review]. J Neurooncol 2005;75(2):149-55.
Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11(24 Pt 1):8600-5.
Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005;12(6):994-1005.
Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24(52):7802-16.
Aghi M, Rabkin S. Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther 2005;7(5):419-30.
Hoh BL, Aghi M, Pryor JC, Ogilvy CS. Heparin-induced thrombocytopenia Type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery 2005;57(2):243-8; discussion 243-8.
Aghi M, Coumans JV, Brisman JL. Subarachnoid hematoma, hydrocephalus, and aseptic meningitis resulting from a high cervical myelogram. J Spinal Disord Tech 2004;17(4):348-51. Erratum in: J Spinal Disord Tech 2005;18(2):207.
Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003;21(2):278-92.
Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2(3):148-64.
Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59(16):3861-5.
Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91(14):1233-41.
Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90(5):370-80.
